4. Pain Management

Learning Objectives

• Describe the pain pathway from nociceptor to cortex and explain where each drug class acts
• Differentiate nociceptive, neuropathic, and mixed/nociplastic pain and why the distinction changes treatment
• Explain the principle of multimodal analgesia and why it reduces opioid consumption
• Compare the major analgesic drug classes (opioids, NSAIDs, acetaminophen, gabapentinoids, local anesthetics) by mechanism and key risk
• Describe how regional techniques (neuraxial and peripheral nerve blocks) fit into perioperative pain plans
• Apply the WHO analgesic ladder concept to acute and chronic pain scenarios
• Recognize red flags for opioid-induced respiratory depression and chronic pain complications

Quick Answer

Pain management in anesthesiology means matching the right drug or technique to the type and severity of pain while minimizing harm — especially opioid-related respiratory depression and dependence. The modern approach is multimodal analgesia: combining drugs that act at different points in the pain pathway (NSAIDs/acetaminophen peripherally, gabapentinoids and local anesthetics on nerve conduction, opioids centrally) so each drug can be used at a lower, safer dose while total pain relief improves. Regional techniques — nerve blocks and neuraxial anesthesia — provide dense, opioid-sparing analgesia at the source. Chronic pain requires a different mindset entirely: it is treated as a disease of the nervous system itself, not just a symptom, so management shifts toward function restoration, interventional procedures, and psychological therapy rather than escalating opioids.

Understanding Pain: The Pathway Matters

Before picking a drug, you need to know where in the pain pathway you're intervening — this is the single most useful mental model in this topic, and it's exactly how exam questions are framed ("which drug acts at the dorsal horn?").

Pain signaling has four steps, and every analgesic drug class targets one of them:

1. Transduction — a noxious stimulus (heat, pressure, chemical mediators like prostaglandins, bradykinin, histamine) is converted into an electrical signal at peripheral nociceptor endings. NSAIDs act here by blocking prostaglandin synthesis (COX-1/COX-2 inhibition), which reduces the sensitizing effect of inflammatory mediators on nociceptors.
2. Transmission — the signal travels along A-delta fibers (fast, sharp, well-localized pain) and C fibers (slow, dull, poorly localized pain) to the dorsal horn of the spinal cord, then up the spinothalamic tract to the thalamus and cortex. Local anesthetics block transmission anywhere along this route by inhibiting voltage-gated sodium channels on axons — this is why a nerve block or epidural can eliminate pain from an entire dermatome.
3. Modulation — the dorsal horn is not a passive relay; descending pathways from the brainstem (using serotonin and norepinephrine) and local interneurons (using GABA and endogenous opioids) can amplify or dampen the signal before it ascends. This is the basis of the Gate Control Theory: large-diameter touch fibers (A-beta) can "close the gate" on pain transmission, which is why rubbing an injured area or using TENS provides relief. Gabapentinoids (gabapentin, pregabalin) act here by binding the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release — especially useful for neuropathic pain where this modulation is dysregulated.
4. Perception — the cortex and limbic system interpret the signal as pain, coloring it with emotional and cognitive context. Opioids act throughout the CNS (spinal and supraspinal mu-receptors) to blunt both the signal and its perceived unpleasantness, which is why they're so effective but also why they affect mood and can be misused.

Central sensitization is what happens when steps 3 and 4 go wrong over time: repeated or intense nociceptive input causes NMDA-receptor-mediated changes in the dorsal horn that lower the pain threshold and expand the receptive field. This is why unrelieved acute pain (e.g., inadequately treated post-surgical pain) is a major risk factor for chronic pain — the nervous system "learns" to be more sensitive. This is also why preemptive and multimodal analgesia matter clinically, not just as textbook buzzwords: blocking the pathway before central sensitization sets in genuinely changes outcomes.

Classifying Pain (and Why It Changes Your Plan)

Type	Mechanism	Classic examples	Best-responding drugs
Nociceptive	Normal nociceptor activation by tissue damage/inflammation	Surgical incision, fracture, arthritis	NSAIDs, acetaminophen, opioids
Neuropathic	Damage or dysfunction of nervous system itself	Diabetic neuropathy, postherpetic neuralgia, phantom limb pain	Gabapentinoids, TCAs, SNRIs (poorly responsive to NSAIDs/opioids alone)
Nociplastic (central sensitization)	Altered pain processing without clear tissue or nerve damage	Fibromyalgia, chronic low back pain without radiculopathy	Multimodal approach, CBT, exercise, SNRIs
Visceral	Poorly localized, referred, autonomic symptoms	Bowel distension, biliary colic	Opioids, antispasmodics; local anesthetics less effective

Mixed pain is common — a post-thoracotomy patient has nociceptive incisional pain plus neuropathic intercostal nerve injury pain, which is exactly why a single drug class rarely suffices and multimodal therapy is the default, not the exception.

Multimodal Analgesia: The Core Strategy

Multimodal analgesia means combining agents with different mechanisms so their effects add up while their side effects don't. This is the anesthesiologist's central strategy for both acute and chronic pain, and it is what distinguishes modern practice from the older "opioid-only" model.

A typical multimodal perioperative regimen:

• Acetaminophen (scheduled, not PRN) — central COX inhibition and modest additional mechanisms; low side-effect burden
• NSAID (e.g., ketorolac IV or ibuprofen) — peripheral anti-inflammatory action; avoid in renal impairment, active GI bleeding, or high bleeding-risk surgery
• Gabapentinoid (gabapentin or pregabalin, single preoperative dose or short course) — reduces opioid requirement and is especially helpful when neuropathic pain is anticipated
• Regional technique (nerve block, epidural, or wound infiltration) — dense, localized analgesia that dramatically reduces opioid need
• Opioid — reserved as the "rescue" or supplemental layer for breakthrough pain, at the lowest effective dose

The payoff of this approach is measurable: it reduces total opioid consumption (opioid-sparing), which lowers rates of nausea, ileus, sedation, and respiratory depression, and appears to reduce the incidence of chronic post-surgical pain by limiting central sensitization.

Pharmacological Interventions

Opioids

Mu-receptor agonists remain the most potent analgesics for moderate-to-severe acute pain, but they carry the biggest safety burden of any analgesic class.

• Common agents: morphine, fentanyl, hydromorphone, oxycodone
• Route matters: IV for acute titration, PCA (patient-controlled analgesia) for post-surgical pain — it lets patients self-titrate within safety limits and generally improves satisfaction without increasing total dose compared to nurse-administered dosing
• Key risks: respiratory depression (dose-dependent, worsened by concurrent sedatives), tolerance, hyperalgesia with prolonged high-dose use, constipation, and dependence with chronic use
• Reversal: naloxone (competitive mu-antagonist) for overdose — remember its half-life is shorter than most opioids, so re-sedation can occur and repeat dosing or an infusion may be needed

Non-Opioid Analgesics

• NSAIDs (ibuprofen, ketorolac, celecoxib): inhibit COX-1/COX-2, reducing prostaglandin-mediated sensitization. Ketorolac is a workhorse IV NSAID in the perioperative period but is limited to short courses (typically ≤5 days) because of bleeding and renal risk.
• Acetaminophen: mechanism is not fully settled but involves central COX inhibition and modulation of descending serotonergic pathways. Minimal effect on platelets or the GI mucosa — a reason it's a default first-line agent even in patients where NSAIDs are contraindicated.

Local Anesthetics

Block voltage-gated sodium channels on axons, producing reversible conduction blockade. Used topically, via infiltration, as peripheral nerve blocks, or neuraxially (spinal/epidural).

• Agents: lidocaine (fast onset, shorter duration), bupivacaine and ropivacaine (longer duration, used for postoperative blocks and epidurals)
• Key safety issue: local anesthetic systemic toxicity (LAST) — accidental intravascular injection or absorption of large doses causes CNS excitation (perioral tingling, tinnitus, seizures) progressing to cardiovascular collapse. Bupivacaine is more cardiotoxic than lidocaine. Treatment is 20% intralipid (lipid emulsion) infusion, which acts as a "lipid sink" to pull the drug out of cardiac tissue — this is a classic exam fact.

Adjuvant Medications

Drugs not designed primarily as analgesics but that enhance pain control:

• Gabapentin/pregabalin: neuropathic pain, perioperative opioid-sparing
• Alpha-2 agonists (dexmedetomidine, clonidine): reduce sympathetic outflow and opioid requirement, used as adjuncts in regional blocks and sedation
• Ketamine: NMDA-receptor antagonist; low-dose infusions reduce central sensitization and opioid requirement, especially valuable in opioid-tolerant patients
• Tricyclic antidepressants and SNRIs (amitriptyline, duloxetine): first-line for neuropathic and nociplastic chronic pain, acting on descending modulatory pathways

Regional Anesthesia and Interventional Techniques

Regional techniques deliver analgesia directly to the pain pathway, sparing systemic opioid exposure entirely or substantially.

• Neuraxial (epidural/spinal): excellent for major abdominal, thoracic, and lower-limb surgery; a continuous epidural infusion of dilute local anesthetic (often with an opioid) provides ongoing postoperative pain control
• Peripheral nerve blocks: single-injection or continuous catheter techniques (e.g., femoral, interscalene, TAP block) targeting a specific surgical site — reduce opioid need and improve early mobilization
• Interventional chronic pain procedures: epidural steroid injections, facet joint injections, radiofrequency ablation of sensory nerves, and spinal cord stimulation for pain refractory to medical management

Non-Pharmacological Approaches

These matter most in chronic pain, where the goal shifts from eliminating pain to restoring function:

• Physical therapy and graded exercise: improves function and can reduce central sensitization over time
• Cognitive behavioral therapy (CBT): addresses the cognitive-emotional amplification of pain — has strong evidence in chronic and nociplastic pain
• TENS (transcutaneous electrical nerve stimulation): exploits gate control theory by stimulating large-diameter afferents
• Mindfulness-based stress reduction, acupuncture, biofeedback: modest but real evidence as adjuncts, not replacements for the above

The WHO Analgesic Ladder — Still a Useful Framework

Originally designed for cancer pain, this stepwise model is a useful teaching scaffold for any escalating pain plan:

1. Step 1 (mild pain): non-opioid (acetaminophen or NSAID) ± adjuvant
2. Step 2 (moderate pain): weak opioid (tramadol, codeine) + Step 1 agents ± adjuvant
3. Step 3 (severe pain): strong opioid (morphine, oxycodone, fentanyl) + Step 1 agents ± adjuvant

Modern acute perioperative practice modifies this into a multimodal "ladder from the start" — you don't wait for non-opioids to fail before adding a regional block; you layer therapies from the outset to prevent central sensitization rather than chase pain after it develops.

Case Vignettes

Acute post-surgical pain — total hip replacement: A 35-year-old woman undergoing elective hip replacement receives a multimodal plan: preoperative gabapentin, scheduled acetaminophen and ketorolac, a continuous epidural infusion of ropivacaine for the first 48 hours, and IV fentanyl PCA for breakthrough pain. Because most of her pain is controlled regionally, her total opioid consumption is low, she avoids significant sedation, and she mobilizes with physiotherapy on postoperative day one — the outcome multimodal analgesia is specifically designed to produce.

Chronic low back pain with radiculopathy: A 50-year-old man with lumbar disc herniation and burning leg pain (neuropathic component) is managed with a slow opioid taper, gabapentin for the neuropathic pain, an epidural steroid injection for the inflammatory component, and a structured CBT and exercise program. The plan targets function, not zero pain — a key mindset shift from acute to chronic pain management.

Key Terms

Term	Definition	Related Concept
Nociception	Neural process of encoding and processing noxious stimuli	First step distinguishing pain from perception
Central sensitization	Increased excitability of dorsal horn/CNS neurons after repeated nociceptive input, lowering pain threshold	Chronic post-surgical pain, neuropathic pain
Multimodal analgesia	Combining drugs with different mechanisms to maximize analgesia and minimize any single drug's dose/side effects	Opioid-sparing strategy
Gate control theory	Large-diameter touch fibers can inhibit pain transmission at the dorsal horn	TENS, mechanism behind "rubbing it better"
PCA (patient-controlled analgesia)	Device allowing patient self-administration of opioid boluses within preset safety limits	Post-surgical opioid delivery
LAST (local anesthetic systemic toxicity)	CNS/cardiac toxicity from excess local anesthetic absorption or intravascular injection	Treated with intralipid emulsion
Gabapentinoids	Gabapentin/pregabalin; bind alpha-2-delta calcium channel subunit to reduce neurotransmitter release	Neuropathic pain, opioid-sparing adjuncts
WHO analgesic ladder	Stepwise framework escalating from non-opioids to strong opioids based on pain severity	Cancer pain, general pain-plan teaching tool
Neuraxial anesthesia	Spinal or epidural administration of local anesthetic/opioid	Major surgery pain control
Opioid-induced hyperalgesia	Paradoxical increase in pain sensitivity from prolonged high-dose opioid exposure	Chronic opioid use, tolerance

Common Mistakes

Misconception: Higher pain scores always mean the patient needs more opioid. Why it's wrong: Pain scores don't distinguish nociceptive from neuropathic or nociplastic pain, and opioids are poorly effective for neuropathic and central-sensitization pain. Escalating opioids in these cases increases side effects without proportionate benefit and can worsen outcomes through tolerance or hyperalgesia. Correct understanding: A high pain score should prompt reassessment of the pain type and whether a non-opioid mechanism (nerve block, gabapentinoid, addressing a surgical complication) is missing from the plan — not an automatic opioid increase.

Misconception: Multimodal analgesia just means "give more drugs." Why it's wrong: The point of multimodal therapy is mechanistic diversity at lower individual doses, not polypharmacy. Adding two opioids together, for example, is not multimodal — it's just additive opioid risk with no mechanistic benefit. Correct understanding: Multimodal analgesia specifically means combining agents that act at different points in the pain pathway (e.g., NSAID + local anesthetic block + low-dose opioid), which is what allows each drug's dose — and therefore its side effects — to go down while total analgesia improves.

Misconception: Chronic pain is just acute pain that has lasted a long time, so it should be treated the same way with stronger or longer opioid courses. Why it's wrong: Chronic pain frequently involves central sensitization and psychosocial amplification rather than ongoing tissue damage. Long-term opioids for chronic non-cancer pain have poor evidence for sustained functional improvement and carry major risks (dependence, hyperalgesia, overdose). Correct understanding: Chronic pain is treated as a distinct condition targeting the nervous system and function, using multidisciplinary care (physical therapy, CBT, adjuvant medications, interventional procedures) with opioids reserved for carefully selected cases and tapered when possible.

Comparison and Connections

Feature	Acute Pain Management	Chronic Pain Management
Primary goal	Eliminate/minimize pain quickly, enable recovery	Restore function; pain may not fully resolve
Typical pathophysiology	Nociceptive (tissue injury)	Often neuropathic or nociplastic (sensitized CNS)
First-line drugs	Scheduled acetaminophen/NSAID + regional block + opioid rescue	Gabapentinoids, SNRIs/TCAs, non-drug therapy first
Opioid role	Central to short-term plan, tapered rapidly	Reserved, carefully monitored, avoided long-term when possible
Team involved	Anesthesiologist, surgical team, acute pain service	Multidisciplinary: pain medicine, PT, psychology, psychiatry
Time horizon	Days to weeks	Months to years
Key risk if mismanaged	Undertreated acute pain → chronic post-surgical pain	Opioid dependence, functional decline

Practice Questions

Recall

1. Name the four steps of the pain pathway. Answer guidance: Transduction (peripheral nociceptor), transmission (nerve fibers to dorsal horn and up the spinothalamic tract), modulation (dorsal horn/descending pathways), and perception (thalamus/cortex).

2. What is the antidote for local anesthetic systemic toxicity? Answer guidance: 20% intralipid (lipid emulsion) infusion, which sequesters the lipophilic local anesthetic away from cardiac tissue; supportive care and seizure management are given alongside it.

Understanding

3. Explain why multimodal analgesia reduces opioid-related side effects even when total analgesia improves. Answer guidance: Each added drug acts at a different point in the pathway, so smaller doses of any single agent (especially the opioid) are needed to achieve the same or better analgesic effect, which lowers the dose-dependent side effects (respiratory depression, sedation, nausea) tied to that agent.

4. Why are gabapentinoids more effective than NSAIDs for neuropathic pain? Answer guidance: Neuropathic pain arises from nerve damage/dysfunction and abnormal central processing (calcium-channel-mediated hyperexcitability at the dorsal horn), not from prostaglandin-driven peripheral inflammation, so NSAIDs (which act on transduction) have little target to act on, while gabapentinoids directly dampen the abnormal central transmission.

Application

5. A patient on a fentanyl PCA becomes increasingly sedated with a respiratory rate of 6/min. What do you do? Answer guidance: Stop/pause the PCA immediately, apply supplemental oxygen, stimulate the patient, and give titrated naloxone (small IV doses to reverse respiratory depression without fully reversing analgesia). Monitor closely afterward since naloxone's duration is shorter than fentanyl's, risking re-sedation.

6. A patient scheduled for major abdominal surgery has chronic kidney disease. Which non-opioid analgesic should you avoid or use cautiously, and what would you substitute? Answer guidance: Avoid or minimize NSAIDs (nephrotoxic, reduce renal blood flow via prostaglandin inhibition). Substitute scheduled acetaminophen, regional/neuraxial technique for dense analgesia, and gabapentinoid adjuncts (with dose adjustment for renal function) as part of a multimodal plan.

Analysis

7. Compare how you would approach a patient with acute postoperative incisional pain versus a patient with 8 months of unexplained low back pain and no red flags. Answer guidance: Acute incisional pain is nociceptive and time-limited — treat aggressively with multimodal analgesia and regional techniques to control pain quickly and prevent central sensitization. Chronic low back pain without red flags is likely nociplastic/mixed — the plan should emphasize function, exercise, CBT, and non-opioid adjuncts, with imaging and opioids reserved rather than first-line, since the pain is unlikely to resolve completely and the goal shifts to functional restoration.

8. Why might inadequately treated acute pain increase the risk of a patient developing chronic pain later? Answer guidance: Sustained or intense unrelieved nociceptive input drives NMDA-receptor-mediated central sensitization in the dorsal horn, lowering pain thresholds and expanding receptive fields. This maladaptive plasticity can persist after the original tissue injury heals, producing chronic pain — which is the physiological rationale for aggressive, preemptive multimodal analgesia in the perioperative period.

FAQ

Why don't anesthesiologists just use higher doses of one strong opioid instead of combining multiple drugs? Opioid side effects (respiratory depression, sedation, nausea, ileus, and with prolonged use, tolerance and hyperalgesia) are dose-dependent. Combining drugs with different mechanisms achieves comparable or better analgesia at a fraction of the opioid dose, which is why multimodal analgesia rather than "just more opioid" is now the standard of care in perioperative medicine.

Is it true that treating pain aggressively after surgery can prevent chronic pain? There's good mechanistic and clinical support for this. Persistent, unrelieved acute pain drives central sensitization, and chronic post-surgical pain is a recognized complication with rates as high as 10-50% depending on the surgery type (e.g., thoracotomy, amputation). Adequate multimodal and regional analgesia in the perioperative period is associated with lower rates of chronic post-surgical pain, though it isn't a guarantee.

Why is ketamine used for pain when it's known as an anesthetic and a drug of abuse? At sub-anesthetic ("low-dose") infusion rates, ketamine's NMDA-receptor antagonism disrupts central sensitization and provides opioid-sparing analgesia without producing the dissociative anesthetic effects seen at higher doses. It's particularly valuable in opioid-tolerant patients and in preventing hyperalgesia, though psychomimetic side effects (vivid dreams, dissociation) can occur even at low doses.

What's the difference between physical dependence, tolerance, and addiction with opioids? Physical dependence (withdrawal symptoms if stopped abruptly) and tolerance (needing more drug for the same effect) are expected physiological adaptations that occur with any patient on opioids for more than a few days — they are not addiction. Addiction is a behavioral disorder involving compulsive use despite harm and loss of control. Confusing these terms leads to both undertreatment of legitimate pain (out of fear of "addicting" patients) and failure to recognize true opioid use disorder when it occurs.

Why do chronic pain plans emphasize function over pain scores? Chronic pain, especially nociplastic pain, often cannot be reduced to zero because the abnormality lies in pain processing itself rather than ongoing tissue damage. Chasing a pain score of zero with escalating opioids has poor evidence for improving quality of life and carries real harm. Measuring and improving function (return to work, activity tolerance, sleep) gives a more meaningful and achievable treatment target.

Quick Revision

• Pain pathway: transduction → transmission → modulation → perception; each analgesic class targets a different step
• NSAIDs/acetaminophen act peripherally/centrally on prostaglandin pathways (transduction); local anesthetics block Na+ channels (transmission); gabapentinoids act on Ca2+ channels at the dorsal horn (modulation); opioids act on mu-receptors throughout CNS (perception)
• Central sensitization = NMDA-mediated increase in CNS excitability from unrelieved nociceptive input; drives chronic post-surgical and neuropathic pain
• Multimodal analgesia = combine mechanisms, not doses of the same class, to lower opioid requirement and side effects
• Nociceptive pain responds to NSAIDs/opioids; neuropathic pain responds better to gabapentinoids, TCAs, SNRIs
• LAST (local anesthetic systemic toxicity) is treated with 20% intralipid infusion
• PCA lets patients self-titrate opioids safely within preset limits; naloxone reverses overdose but has a shorter half-life than most opioids
• WHO ladder: non-opioid → weak opioid → strong opioid, each step adding to (not replacing) the prior step
• Regional/neuraxial techniques provide dense, opioid-sparing analgesia and are central to modern perioperative plans
• Chronic pain management targets function restoration via multidisciplinary care (PT, CBT, adjuvants), not just pain elimination
• Tolerance and physical dependence are expected with chronic opioid use and are distinct from addiction

Related Topics

Prerequisites: Neurophysiology of pain, basic pharmacology, General Anesthesia Techniques

Related Topics: Regional Anesthesia Techniques, perioperative monitoring, opioid pharmacology, neuromuscular blockade

Next Topics: Regional Anesthesia Techniques, Anesthesia Complications and Patient Safety